Planned Parenthood wins partial victory in legal fight with Trump administration over funding cuts
A provision in that bill would end Medicaid payments to abortion providers for one year.
But U.S. District Judge Indira Talwani in Boston granted a preliminary injunction Monday that, for now, blocks the government from cutting Medicaid payments to Planned Parenthood member organizations that either don't provide abortion care or didn't meet a threshold of at least $800,000 in Medicaid reimbursements in a given year.
It wasn't immediately clear how many Planned Parenthood organizations and clinics would continue to get Medicaid reimbursement under that decision and how many might not.
The lawsuit was filed earlier this month against Health and Human Services Secretary Robert F. Kennedy Jr. by Planned Parenthood Federation of America and its member organizations in Massachusetts and Utah.
A Planned Parenthood spokesperson said its lawyers were still examining the order and would release a statement shortly.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
UnitedHealth Group (UNH) Responds to the Department of Justice
UnitedHealth Group Incorporated (NYSE:UNH) is one of the top low volatility healthcare stocks to buy now. On July 24, UnitedHealth Group Incorporated (NYSE:UNH) released a statement responding to the Department of Justice after a review of the media reports about investigations into specific aspects of its involvement in the Medicare program. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) stated that it has now begun complying with the formal criminal and civil requests from the Department, and has 'full confidence in its practices and is committed to working cooperatively with the Department throughout this process'. It added that UnitedHealth Group Incorporated (NYSE:UNH) has a historical record of 'responsible conduct and effective compliance,' with independent CMS audits showing that its practices are ranked 'among the most accurate in the industry.' Management stated that after a decade-long civil challenge by the Department to aspects of the company's Medicare Advantage business, 'a court-appointed Special Master concluded there was no evidence to support claims of wrongdoing'. UnitedHealth Group Incorporated (NYSE:UNH) has launched its own initiative to provide confidence and transparency to stakeholders, focusing on conducting 'third-party reviews of policies, practices, and associated processes and performance metrics for risk assessment coding, managed care practices, and pharmacy services.' UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments, which have solid operations. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
17 minutes ago
- Yahoo
'Total Mental Collapse': Trump Ripped After 'Insane' New Ramble In Europe
President Donald Trump spent part of his weekend in Scotland reviving his old grievances against wind power, even claiming at one point that it was 'killing' Americans. During a meeting with European Commission President Ursula von der Leyen, Trump abruptly detoured from immigration to wind turbines. 'And the other thing I say to Europe: We will not allow a windmill to be built in the United States,' Trump said. 'They're killing us.' He added: 'They're killing the beauty of our scenery, our valleys, our beautiful plains ― and I'm not talking about airplanes. I'm talking about beautiful plains, beautiful areas in the United States, and you look up and you see windmills all over the place. It's a horrible thing. It's the most expensive form of energy. It's no good. They're made in China, almost all of them.' He complained that wind turbines 'rust and rot in eight years,' and then can't be 'buried' because they will harm the soil. 'The whole thing is a con job,' he said. 'It's very expensive. And in all fairness, Germany tried it and wind doesn't work.' Much of what the president said was wildly inaccurate: Germany gets more than a quarter of its energy from wind, turbines last about 30 years (not eight) according to the U.S Department of Energy, it's not the most expensive form of energy, and they're not 'almost all' made in China. Several users asked Grok, the AI tool within X, to fact-check Trump's claims on wind power. Here's a typical response: Trump, who has frequently attacked renewable energy, has a special hatred of wind power that likely began some two decades ago, when an offshore wind farm was proposed near the land that would become his golf resort in Scotland. He sued to block it, lost, and has complained about wind and other forms of renewable energy since. He mentioned that on Sunday as well. 'Today I'm playing the best course I think in the world, Turnberry ― even though I own it ― it's probably the best course in the world, right?' he said. 'And I look over the horizon and I see nine windmills... I said, 'Isn't that a shame? What a shame.'' Trump has previously taken his anti-wind stance to absurd extremes, such as in 2019, when he falsely claimed wind turbines cause cancer. 'The wind, the wind, it sounds so wonderful,' he said last year. 'The wind, the wind, the wind is, the wind is bullshit, I'll tell you.' Trump's critics called him out for his latest out-of-the-blue tirade against wind energy:
Medscape
19 minutes ago
- Medscape
Cancer Care Costs High Among Privately Insured Patients
TOPLINE: A recent analysis found that privately insured US patients with newly diagnosed cancer, especially those with more advanced disease, had 'substantial out-of-pocket costs.' Monthly out-of-pocket costs among these patients increased by a mean of almost $600, on average, but increased to nearly $720 per month for those with stage IV disease. METHODOLOGY: Out-of-pocket costs for cancer care in the US are rising, but most research has focused on Medicare beneficiaries. It's important to understand privately insured patients' financial burdens, especially with cancer rates growing among younger Americans. Researchers conducted a retrospective study of 19,656 patients with cancer, using a dataset that links claims from a large private insurer to the Surveillance, Epidemiology, and End Results cancer registry. Overall, 74.1% had breast cancer, 14.5% had colorectal cancer, and 11.4% had lung cancer. Analyses also included 26,502 individuals without cancer who were assigned pseudo – diagnosis date. Monthly out-of-pocket costs (copays, co-insurance, and deductibles) were calculated from claims and inflation-adjusted to 2024 US dollars. TAKEAWAY: After a cancer diagnosis, monthly out-of-pocket costs rose by $592, on average. Those added costs increased with disease stage, from $462 per month for stage 0 cancer to $720 per month for stage IV cancer. Out-of-pocket costs spiked in the month of diagnosis and remained elevated for 6 months compared with those in individuals without cancer — totaling an average of $4145 in cumulative additional costs (over 7 months). IN PRACTICE: 'In this cohort study, patients with private insurance were found to have high OOPCs [out-of-pocket costs] after an incident diagnosis of cancer, and those with the most advanced cancer had the highest OOPCs,' the authors wrote. 'The variability in OOPCs based on cancer stage underscores the need for policies such as paid sick leave, that address both insurance continuity and financial assistance, especially for patients with more advanced cancer.' SOURCE: This study, led by Liam Rose, PhD, Stanford University School of Medicine, Palo Alto, California, was published online in JAMA Network Open. LIMITATIONS: Differential insurance attrition could have affected the results: Patients with stage IV cancer were most likely to drop their coverage. The study could only capture direct medical costs, which misses other potential financial burdens, such as lost income and travel expenses. DISCLOSURES: This study received funding support through a grant from the American Cancer Society. One author reported receiving grants from the Department of Veterans Affairs and National Institutes of Health during the conduct of the study. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
